Amundi Has $79.58 Million Holdings in DaVita Inc. $DVA

Key Points

• Amundi increased its stake in DaVita Inc. by 16.0%, holding 517,690 shares worth approximately $79.58 million after purchasing an additional 71,304 shares during the first quarter.
• DaVita reported earnings of $2.95 per share for the latest quarter, exceeding analysts' expectations, with revenue rising 6.1% year-over-year to $3.38 billion.
• Hedge funds and institutional investors currently own 90.12% of DaVita's stock, reflecting strong interest from these entities.

Amundi increased its stake in DaVita Inc. (NYSE:DVA - Free Report) by 16.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 517,690 shares of the company's stock after acquiring an additional 71,304 shares during the quarter. Amundi owned approximately 0.67% of DaVita worth $79,584,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of DVA. Stifel Financial Corp boosted its holdings in shares of DaVita by 3.2% in the fourth quarter. Stifel Financial Corp now owns 5,937 shares of the company's stock worth $888,000 after buying an additional 185 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of DaVita by 27.2% in the fourth quarter. Ameriprise Financial Inc. now owns 32,545 shares of the company's stock worth $4,867,000 after buying an additional 6,951 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of DaVita in the fourth quarter worth about $322,000. Crestline Management LP boosted its holdings in shares of DaVita by 19.1% in the fourth quarter. Crestline Management LP now owns 5,034 shares of the company's stock worth $753,000 after buying an additional 808 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in shares of DaVita in the fourth quarter worth about $106,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on DVA shares. Truist Financial set a $148.00 price target on DaVita in a report on Friday, August 8th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a report on Friday, August 22nd. Bank of America lowered their price target on DaVita from $145.00 to $140.00 and set an "underperform" rating on the stock in a report on Wednesday. Finally, Barclays lowered their price target on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, DaVita currently has a consensus rating of "Reduce" and a consensus target price of $158.00.

DaVita Stock Down 0.1%

DVA stock traded down $0.16 during mid-day trading on Friday, hitting $133.08. The stock had a trading volume of 481,674 shares, compared to its average volume of 673,038. The stock has a market capitalization of $9.52 billion, a price-to-earnings ratio of 13.09, a PEG ratio of 0.95 and a beta of 1.13. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 1-year low of $126.07 and a 1-year high of $179.60. The company has a fifty day moving average of $138.45 and a 200 day moving average of $141.54.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.70 by $0.25. The business had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The firm's revenue was up 6.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, equities analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Insider Activity

In other news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the sale, the insider directly owned 26,038 shares in the company, valued at $3,905,700. The trade was a 8.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.50% of the stock is currently owned by corporate insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.